[Rivaroxaban versus warfarin in high-risk patients with antiphospholipid syndrome]
Z Rheumatol
.
2019 Aug;78(6):550-551.
doi: 10.1007/s00393-019-0659-y.
[Article in German]
Author
Denitsa Hadjiski
1
Affiliation
1
Tätigkeitschwerpunkt Klinische Immunologie, Praxis für Rheumatologie, Beethovenstr. 2, 76530, Baden-Baden, Deutschland. d.hadjiski@rheuma-badenbaden.de.
PMID:
31250081
DOI:
10.1007/s00393-019-0659-y
No abstract available
MeSH terms
Anticoagulants / therapeutic use
Antiphospholipid Syndrome* / drug therapy
Humans
Rivaroxaban* / therapeutic use
Warfarin* / therapeutic use
Substances
Anticoagulants
Warfarin
Rivaroxaban